Lemtrada (alemtuzumab) / Sanofi 
Welcome,         Profile    Billing    Logout  
 8 Diseases   17 Trials   17 Trials   2602 News 


«12...13141516171819202122232425»
  • ||||||||||  Zinbryta (daclizumab) / Biogen, AbbVie, Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
    Review, Journal:  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. (Pubmed Central) -  Mar 4, 2020   
    Here we review established and emerging risks associated with multiple sclerosis biologic agents, with an emphasis on their immunological adverse effects. We also discuss the specific challenges that multiple sclerosis biologics pose to drug safety systems, and the potential for improvements in safety frameworks.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    [VIRTUAL] TC12: How to handle safety issues in multiple sclerosis treatment - Level 2 (Room Copenhagen) -  Mar 2, 2020 - Abstract #EAN2020EAN_283;    
    Secondary autoimmunity has been observed after Alemtuzumab treatment; its pathophysiology and how to minimise the risk will also be discussed. Finally, the recommendation on how to prevent risk connected with pregnancy and how to handle disease reactivation will be discussed.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis. (Pubmed Central) -  Feb 24, 2020   
    We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty, Lemtrada (alemtuzumab) / Sanofi
    Trial primary completion date:  Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) -  Feb 23, 2020   
    P4,  N=40, Active, not recruiting, 
    While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors. Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Journal:  Highly active multiple sclerosis: options for monoclonal antibody therapy (Pubmed Central) -  Feb 21, 2020   
    The review presents data on the effectiveness of three monoclonal antibody drugs - natalizumab, alemtuzumab and ocrelizumab. In addition, updated data on the safety of monoclonal antibodies are presented to help the physician make a balanced choice of a drug and therapy strategy.
  • ||||||||||  Tysabri (natalizumab) / Biogen, fingolimod / Generic mfg., Lemtrada (alemtuzumab) / Sanofi
    Temporal Trends in the Diagnosis of Neuromyelitis Optica Spectrum Disorder in US Insurance Claims Databases From 2001 to 2017 (Exhibit Hall A, Convention Center - Board no. P206) -  Feb 21, 2020 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_409;    
    Conclusions Despite changes to the NMOSD diagnostic guidelines, real-world use of AQP4-IgG testing remains modest, and the proportion of patients with NMOSD receiving an MS Dx or DMT has not substantially changed. These results highlight the unmet need for appropriate diagnosis and treatment of NMOSD.
  • ||||||||||  Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
    Safety Of Sequencing From Anti-CD20 Therapy To Alemtuzumab Case Series. (Exhibit Hall A, Convention Center - Board no. P116) -  Feb 21, 2020 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_252;    
    Sequencing anti-CD20 and alemtuzumab has been a successful treatment regimen in this limited case series. Larger studies with a longer follow up period should determine if sequencing these agents has an impact on the incidence of secondary autoimmunity following alemtuzumab therapy, and whether this sequencing increases risk for infection or severe neutropenia.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Serum Neurofilament Light Chain Levels as an Indicator of Treatment Response in CARE-MS I Patients (Exhibit Hall A, Convention Center - Board no. P017) -  Feb 21, 2020 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_178;    
    P3
    Low sNfL levels on treatment were significantly associated with decreased relapse rates, MRI disease activity, and BVL over 2 years in pooled CARE-MS I patients, supporting the potential for sNfL to detect treatment response. Study Support: Sanofi
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Safety And Efficacy Of Alemtuzumab Treatment In Slovakia (Exhibit Hall A, Convention Center - Board no. P027) -  Feb 21, 2020 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_174;    
    The study confirms a positive effect of alemtuzumab on clinic and radiological outcomes. According our experiences, it seems safer to use long-lasting alemtuzumab as one of the first DMTs in RRMS patients with active disease, as using it after three or more DMTs with cumulative effects on the immune system presents a high risk of unpredictable complications.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen, Zenyaku Kogyo, Lemtrada (alemtuzumab) / Sanofi
    Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation For Multiple Sclerosis (Exhibit Hall A, Convention Center - Board no. P051) -  Feb 21, 2020 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_128;    
    For participants randomized to AHSCT, peripheral blood stem cells (PBSC) will be mobilized with cyclophosphamide, dexamethasone, and filgrastim, collected by leukapheresis, and cryopreserved...Participants randomized to BAT will be treated with either natalizumab, alemtuzumab, ocrelizumab, or rituximab... BEAT-MS will be a large scale prospective multi-center randomized clinical trial comparing AHSCT to contemporary high efficacy DMTs, with the goal of determining whether AHSCT is an appropriate treatment option for patients with highly active RMS for whom BAT would be prescribed in current practice.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Alemtuzumab And Prescription Medication Use In The MS Population (Exhibit Hall A, Convention Center - Board no. P105) -  Feb 21, 2020 - Abstract #ACTRIMSForum2020ACTRIMS_FORUM_112;    
    A range of new medications were initiated with the introduction of alemtuzumab, beyond those recommended to minimize adverse effects. While most new prescriptions were filled transiently, the use of antivirals and hypnotics extended beyond the initial infusion period.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Progression of Graves Disease to Hashimoto's Thyroiditis Following Alemtuzumab Therapy for Multiple Sclerosis (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_1875;    
    This case was unique in that the patient developed both TR Ab and TPO Ab after alemtuzumab therapy which resulted in Grave's disease followed by Hashimoto's thyroiditis. The case highlights the importance of continuous monitoring of thyroid function in patients treated with alemtuzumab given the unpredictable autoimmune phenomena which may occur.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Alemtuzumab Induced Graves Disease (ENDOExpo) -  Feb 7, 2020 - Abstract #ENDO2020ENDO_1873;    
    She had no exposure to contrast dye, steroids, amiodarone, supplements or biotin use...She was started on methimazole...We also recommend checking TSI, TPO antibody for high-risk patients (positive family history, past history) and thyroid US for those who have nodules or goiters before starting IRT. For those found to have abnormal TFTs, TSI or TPO, routine follow up with an Endocrinologist should be recommended during, and even after therapy completion.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Effect of Alemtuzumab (LEMTRADA®) Treatment on the Peripheral Immune Repertoire in Multiple Sclerosis Patients () -  Feb 3, 2020 - Abstract #AAN2020AAN_4889;    
    Results analyzed so far show remarkably characteristic patterns of clonal expansion, clonal abundance and clonal evolution/persistence over time of individual lymphocyte subpopulations, which are differentially affected by Alemtuzumab treatment. Further data analysis and correlation with clinical data is ongoing to better understand which of the observed effects are responsible for maintaining immune competence, a beneficial “remolding’’ of auto-aggressive immune components or the development of secondary autoimmune conditions under Alemtuzumab treatment.
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Acute Thrombotic Microangiopathy and Cortical Necrosis Following Administration of Alemtuzumab: A Case Report. (Pubmed Central) -  Feb 1, 2020   
    She received dexamethasone and underwent plasmapheresis, which was unsuccessful at removing alemtuzumab. The patient received renal replacement therapy for approximately 7 weeks, followed by slow recovery of kidney function that returned close to her baseline.
  • ||||||||||  Review, Journal:  Treatment of multiple sclerosis - success from bench to bedside. (Pubmed Central) -  Jan 30, 2020   
    Concomitantly, new monoclonal antibodies (alemtuzumab and ocrelizumab) have been developed and approved...Treatment decisions should account for disease phenotype, prognostic factors, comorbidities, the desire for pregnancy and the patient's preferences in terms of acceptable risk. The development of treatment for MS during the past 25 years is a fantastic success of translational medicine.
  • ||||||||||  Clinical, Review, Journal:  Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. (Pubmed Central) -  Jan 30, 2020   
    Understanding immunological changes induced by IRTs and how they correlate with clinical outcomes will be instrumental in guiding the optimal use of immune reconstitution as a durable therapeutic strategy. This Perspectives article critically discusses the efficacy and potential mechanisms of IRTs in the context of immune system renewal and durable disease remission in MS.
  • ||||||||||  Campath (alemtuzumab) / Sanofi, Lemtrada (alemtuzumab) / Sanofi
    Clinical, Journal:  Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. (Pubmed Central) -  Jan 29, 2020   
    This Perspectives article critically discusses the efficacy and potential mechanisms of IRTs in the context of immune system renewal and durable disease remission in MS. The present document is intended to be used as a tool for optimising the management of alemtuzumab in routine clinical practice.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen, Mavenclad (cladribine) / EMD Serono
    Cladribine: a multicentre LOng-term efficacy Biomarker Australian Study (CLOBAS) () -  Jan 21, 2020 - Abstract #AAN2020AAN_2869;    
    This will be the first trial of cladribine which offers re-initiation of therapy after year 3. Preliminary data suggests extra caution should be used when treating ex-alemtuzumab patients with cladribine tablets to avoid lymphopenia
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Blood pressure changes during Alemtuzumab infusion for persons with MS () -  Jan 21, 2020 - Abstract #AAN2020AAN_2863;    
    Compliance with blood monitoring was very high and most AI were identified pre-symptomatically. This is the first study documenting BP changes during alemtuzumab infusions in PwMS, demonstrating significant increases in BP during all infusions.
  • ||||||||||  Lemtrada (alemtuzumab) / Sanofi
    Effect of Alemtuzumab (LEMTRADA®) Treatment on the Peripheral Immune Repertoire in Multiple Sclerosis Patients () -  Jan 21, 2020 - Abstract #AAN2020AAN_2521;    
    Results analyzed so far show remarkably characteristic patterns of clonal expansion, clonal abundance and clonal evolution/persistence over time of individual lymphocyte subpopulations, which are differentially affected by Alemtuzumab treatment. Further data analysis and correlation with clinical data is ongoing to better understand which of the observed effects are responsible for maintaining immune competence, a beneficial “remolding’’ of auto-aggressive immune components or the development of secondary autoimmune conditions under Alemtuzumab treatment.
  • ||||||||||  Tecfidera (dimethyl fumarate) / Biogen
    Network Meta-Analysis for Cumulative Disability Accumulation in Relapsing Multiple Scelorsis () -  Jan 21, 2020 - Abstract #AAN2020AAN_1859;    
    Ponesimod delays disability accumulation, with an absolute effect size statistically superior to placebo and numerically superior to most currently available DMTs for RMS. Results of the NMA are limited due to the small number of trials reporting HR for CDA.